News Sentiment

ATAI sentiment intelligence

ATAI Life Sciences BV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 35 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.17 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 26

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-0.4% over one week, +31.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

AtaiBeckley Inc. (NASDAQ: ATAI) investor commits 15.4% stake to Lilly deal

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -0.4% Price digesting
Trend fit Trend active 31.9% over four weeks
Fair value 108.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 18
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 26
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingKey 9
simplywall.st 3
Investing.com 3
Investing News Network 3
Markets Mojo 2
TradingView 2
Stock Titan 1

Event Lens

What the news is about

Classified themes
Market update 16
Earnings 13
Deals and strategy 2
Analyst action 2
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 35
TradingKey Direct company coverage

ATAI Life Sciences NV (ATAI) Institutional Confidence

ATAI Life Sciences NV (ATAI) has an institutional shareholding score of 3.00, placing it 192nd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 83.09% quarter-over-quarter, reaching 19.93%. Catherine Wood

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 06:10
Source
TradingKey
TradingKey Direct company coverage

ATAI Life Sciences NV (ATAI) Financial Health: Profitability & Balance Sheet Analysis

ATAI Life Sciences NV (ATAI) currently holds a financial score of 6.24, ranking 275 out of 389 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue decreased by 38.65% year-over-y

Tone
Negative 39/100
Event
Earnings
Published
23 Jun 2026 10:40
Source
TradingKey
TradingKey Direct company coverage

ATAI Life Sciences NV (ATAI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for ATAI Life Sciences NV (ATAI), noting its current valuation score of 6.61, ranking 314th in its industry. It highlights the company's current P/E ratio is -1.43, and mentions that relevant data for P/B, P/S, and P/CF ratios have not y

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 05:10
Source
TradingKey
TradingKey Direct company coverage

ATAI Life Sciences NV (ATAI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of ATAI Life Sciences NV (ATAI), showing its current price momentum score as 7.15 within the Biotechnology & Medical Research industry. It identifies a trading range with resistance at $4.82 and support at $3.49, suggesting suitability f

Tone
Negative 38/100
Event
Market update
Published
19 Jun 2026 04:10
Source
TradingKey
TradingKey Direct company coverage

ATAI Life Sciences NV (ATAI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for ATAI Life Sciences NV (ATAI), showing a current earnings forecast score of 8.43. Analysts have a consensus price target of $12.00, with a strong "Buy" recommendation based on 14 analysts. The company's expected revenue for the next q

Tone
Positive 70/100
Event
Earnings
Published
19 Jun 2026 03:10
Source
TradingKey
TradingKey Direct company coverage

ATAI Life Sciences NV (ATAI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of ATAI Life Sciences NV's (ATAI) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page primarily serves as a financial data portal fo

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 08:39
Source
TradingKey
TradingKey Direct company coverage

ATAI Life Sciences NV (ATAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article for ATAI Life Sciences NV (ATAI) indicates that the company has not yet disclosed relevant data regarding its revenue breakdown by business segment or by region. The page displays ATAI's current stock price, market cap, and links to other financial analysis sections,

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 22:10
Source
TradingKey
TradingKey Direct company coverage

ATAI Life Sciences NV (ATAI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of ATAI Life Sciences NV's shareholder structure, including major shareholders and institutional holdings. It lists the proportion of shares held by various investor types like family offices, investment advisors, and hedge funds, alongs

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 22:10
Source
TradingKey
TradingKey Direct company coverage

TradingKey

The page displays real-time stock information for ATAI Life Sciences NV (ATAI), showing its current price, daily change, and after-hours trading data. It includes a market capitalization and various sections like Overview, Financials, Discussions, and Analysis. The platform also

Tone
Neutral 50/100
Event
Market update
Published
11 May 2026 21:39
Source
TradingKey
Investing.com Direct company coverage

InvestingPro’s fair value model accurately predicted Atai’s 38% decline By Investing.com

InvestingPro's Fair Value analysis accurately predicted a 38% decline in Atai Life Sciences (NASDAQ:ATAI) shares. In October 2025, when the stock traded at $6.45, the model identified significant overvaluation and projected a 35% downside. This prediction was validated as shares

Tone
Negative 28/100
Event
Market update
Published
06 May 2026 07:02
Source
Investing.com
MSN Direct company coverage

atai Life Sciences, Beckley Psytech get FDA breakthrough therapy status for BPL-003

The article reports that atai Life Sciences and Beckley Psytech have received FDA breakthrough therapy designation for their drug candidate BPL-003. This status is granted to therapies that show substantial improvement over available treatments for serious conditions. The article

Tone
Positive 71/100
Event
Market update
Published
11 Apr 2026 04:40
Source
MSN
Markets Mojo Direct company coverage

ATAI Life Sciences Soars 14.75%, Hits Intraday High of $3.91

ATAI Life Sciences NV saw a significant surge in stock price, rising 14.75% to an intraday high of $3.91, significantly outperforming the S&P 500 on the same day and over the past week. Despite impressive annual growth of 157.62%, the company faces year-to-date declines and finan

Tone
Positive 66/100
Event
Market update
Published
30 Mar 2026 22:40
Source
Markets Mojo
TradingView Direct company coverage

AtaiBeckley Inc. Trade Ideas — TRADEGATE:B72

This article compiles various trade ideas and technical analyses for AtaiBeckley Inc. (TRADEGATE:B72), also referred to as ATAI Life Sciences. Traders analyze its stock performance, support and resistance levels, market capitalization, and potential for rebounds, particularly wit

Tone
Positive 77/100
Event
Market update
Published
27 Mar 2026 09:39
Source
TradingView
Investing.com Direct company coverage

H.C. Wainwright reiterates atai Life Sciences stock rating at buy

H.C. Wainwright has reiterated a Buy rating and a $25.00 price target for atai Life Sciences (NASDAQ: ATAI) following a virtual investor day. The company unveiled its ReConnection Phase 3 pivotal program for BPL-003, with trials expected to start in Q2 2026 and topline data in ea

Tone
Positive 94/100
Event
Analyst action
Published
10 Mar 2026 08:16
Source
Investing.com
Investing.com Direct company coverage

Jefferies reiterates atai Life Sciences stock rating on pipeline progress

Jefferies has reiterated a Buy rating and a $10.00 price target for atai Life Sciences (NASDAQ: ATAI), citing significant pipeline advancements. Key developments include BPL-003, an intranasal 5-MeO-DMT treatment, entering two Phase III trials for treatment-resistant depression i

Tone
Positive 71/100
Event
Analyst action
Published
06 Mar 2026 21:53
Source
Investing.com
Markets Mojo Direct company coverage

ATAI Life Sciences Forms Death Cross, Signaling Potential Bearish Trend

ATAI Life Sciences NV has recently formed a "Death Cross," a technical indicator suggesting a potential bearish trend. While the stock has seen a significant annual gain of 123.03%, it has declined by 1.34% today and 5.15% over the past week, resulting in a year-to-date performan

Tone
Neutral 50/100
Event
Market update
Published
03 Mar 2026 12:52
Source
Markets Mojo
Investing News Network Direct company coverage

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

AtaiBeckley Inc. (NASDAQ: ATAI) announced it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will include presentations and Q&A sessions with executive leadership and external key opinion leaders, focusing on the company's mis

Tone
Positive 64/100
Event
Market update
Published
20 Feb 2026 12:52
Source
Investing News Network
Investing News Network Direct company coverage

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

AtaiBeckley Inc. has appointed Michael Faerm as its new Chief Financial Officer, effective March 9, 2026. Faerm brings over 25 years of experience in life sciences finance, equity research, and investment banking, and will oversee the company's financial strategy and capital mark

Tone
Positive 72/100
Event
Market update
Published
19 Feb 2026 14:27
Source
Investing News Network
Bitget Direct company coverage

ATAI Stock Forecast: Analyzing atai Life Sciences Market Outlook

This article provides a stock forecast for atai Life Sciences (ATAI), highlighting a highly optimistic outlook from financial analysts with a "Strong Buy" consensus and significant potential upside. The forecast is driven by progress in their clinical pipeline, particularly BPL-0

Tone
Positive 81/100
Event
Guidance
Published
06 Feb 2026 09:39
Source
Bitget